Amgen Inc.
Amgen Announces Second Quarter 2024 Financial Results
Summary
Amgen Inc. reported a 20% increase in total revenues to $8.4 billion for the second quarter of 2024, compared to $6.99 billion in the second quarter of 2023. Product sales grew by 20%, driven by volume growth, partially offset by lower net selling prices. GAAP earnings per share (EPS) decreased by 46% from $2.57 to $1.38, whereas non-GAAP EPS decreased by 1% from $5.00 to $4.97. Free cash flow for the second quarter was $2.2 billion, down from $3.8 billion in the same period of 2023.
Profitelligence Alerts
Get alerts for AMGN
Be first to know when Amgen Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Official SEC Documents
Advertisement